OBJECTIVE:
To determine the association between asthma and generalized anxiety disorder for adults utilizing a PBM. METHODS: Adult participants (age 18-65 years) were retrospectively identified in Caremark's PBM database and assessed for asthma and generalized anxiety disorder (GAD) from January 2002-September 2002. Using pharmacy algorithms, asthmatic participants and non-asthmatic participants were identified and compared as having GAD where anxiety medication supply exceeded 27 days. Sub-analysis of the asthma population compared the utilization of specific drug classes to the association of anxiety disorder. All populations were compared using odds ratio analysis. RESULTS: A total of 4,238,840 participants (58.5% female) were evaluated over the study period; 205,964 (4.86%) were identified as being asthmatic (60.2% female, mean age 51.5 years, std 15.7 years); 210,972 (4.98%) of the study population were being treated with anti-anxiety medications; and 16,912 (0.4%) of the participants were treated with both. Asthma was associated with a significant increased likelihood of anxiety disorder (OR: 1.77; 95% CI: 1.74 to 1.80). Treatment with steroid inhalants and/or leukotriene modulators was associated with a significant decrease in the likelihood of anxiety disorders among asthmatics (OR: 0.89; 95% CI: 0.87 to 0.92). While treatment with asthma combination medications was associated with a higher significant increased likelihood of GAD among asthmatics (OR: 2.22; 95% CI: 1.72 to 2.86). CONCLUSION: These findings are consistent with previously published self-reported data showing an association between asthma and GAD. In this study, participants treated for asthma were found to be 77% more likely to be treated for GAD than the general non-asthmatic population. Participants using steroid inhalants or leukotriene modulators were 11% less likely to be treated for GAD than other asthmatics. The use of asthma combination therapy was associated with 120% increased likelihood of GAD treatment, possibly indicating the severity of the asthma condition is correlated to an increased likelihood of GAD. Increased attention needs to be placed on the management of anxiety as a comorbidity of asthma. This study compared differences in healthcare costs based upon length of SSRI therapy. METHODS: Continuously eligible patients >18 years of age receiving SSRI therapy diagnosed as having depression in a managed Medicaid program from July 1, 1999 to December 31, 2000 were eligible for study inclusion. Length of therapy was defined as total SSRI days supply acquired within six months of the index date. Patients were placed into the following cohorts based upon length of therapy or drug utilization patterns: 1) <90 days; 2) 90-179 days; 3) >180 days; or 4) Switched/Augmented (SA). Differences in pharmaceutical, professional, hospital and total healthcare costs were evaluated across the four cohorts over a 1-year follow-up period. RESULTS: There were 2250 patients meeting all inclusion criteria. Only 34% of patients received >180 days of therapy. While 24% had <90 days of therapy, 21% had 90-179 days and 21% had evidence of switching/augmentation. Demographic and background covariates were similar across all cohorts. As expected, pharmaceutical charges increased as length of therapy increased, being highest in the SA cohort. However, as length of therapy increased from <90 days to >180 days, professional services and hospital charges decreased by an average of $816 annually per patient. Total monthly healthcare costs in the >180 day cohort remained stable after at least 6 months of SSRI treatment through the full 12-months that patients were followed. CONCLUSIONS: Pharmaceutical costs increased as SSRI length of therapy improves. However, healthcare costs decreased due to reductions in hospital and professional service charges for patients maintained on SSRIs for at least the recommended six months of continuous therapy.
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DRUG UTILIZATION ANALYSIS OF THE SSRI CLASS IN A MEDICAID HMO:THE FLUOXETINE EXPERIENCE
Belazi D, Tegenu M Keystone Mercy Health Plan, Philadelphia, PA, USA OBJECTIVE: There is little research describing the effects of the introduction of generic fluoxetine to the SSRI market. The purpose of this analysis is to examine utilization of the SSRI class in a Pennsylvania Medicaid HMO before and after the launch of fluoxetine (generic) 
